Preoperative Systemic Immune-Inflammation Index (SII) for Predicting the Survival of Patients with Stage I-III Gastric Cancer with a Signet-Ring Cell (SRC) Component
Table 4
Analysis of prognostic factors in 512 patients with gastric cancer with an SRC component.
Variables
Survival analysis
5-YSR (%)
value
Sex
Male
53.3
0.639
Female
51.7
Age (years)
<55
58.5
0.007
≥55
47.4
Tumor size (cm)
<4.75
72.8
<0.001
≥4.75
36.6
Chemotherapy
Yes
56.6
0.059
No
49.3
SRCC
mSRCC
53.6
0.432
pSRCC
47.1
T-stage
T1
97.6
<0.001
T2
82.8
T3
50.0
T4
34.4
N-stage
N0
83.1
<0.001
N1
55.8
N2
47.0
N3a
30.4
N3b
10.3
TNM
I+II
80.9
<0.001
III
31.5
Tumor location
L
59.5
<0.001
M
49.3
U
37.1
LM
37.7
MU
28.6
LMU
21.4
Leukocyte
<6.17
55.1
0.229
≥6.17
49.5
Neutrophil
<3.27
56.9
0.046
≥3.27
48.4
Hemoglobin
<121.2
40.0
<0.001
≥121.2
57.5
Fibrinogen
<3.06
62.3
<0.001
≥3.06
42.2
Prealbumin
<234.5
39.7
<0.001
≥234.5
64.9
Albumin
<42.5
46.2
<0.001
≥42.5
61.4
Globulin
<29.9
54.1
0.170
≥29.9
46.0
NLR
<2.2
59.1
0.006
≥2.2
40.1
PNI
<48.73
38.1
<0.001
≥48.73
60.4
SII
<527
60.0
<0.001
≥527
38.4
Total gastrectomy
Yes
22.1
<0.001
No
61.4
SII: systemic immune-inflammation index; SRCC: signet-ring cell carcinoma; pSRCC: pure signet-ring cell cancer; mSRCC: mixed signet-ring cell cancer; LM: lower and middle; MU: middle and upper; LMU: lower, middle, and upper; PNI: prognostic nutritional index; NLR: lymphocyte to neutrophil ratio.